The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes

Molecular Nutrition and Food Research

Volumn 58, Issue 3, 2014, Pages 516-527

  Schiborr, Christina ^a   Kocher, Alexa ^a   Behnam, Dariush ^b   Jandasek, Josef ^c   Toelstede, Simone ^c   Frank, Jan ^a  

^a UNIVERSITY OF HOHENHEIM   (Germany)

^b AQUANOVA AG   (Germany)

^c Raps GmbH and Co KG   (Germany)

Author keywords

Bioavailability; Curcuma longa; Curcumin; Healthy humans; Safety; Sex differences

Indexed keywords

BIS(4-HYDROXYCINNAMOYL)METHANE; CURCUMIN; DEMETHOXYCURCUMIN; MICELLE; POWDER;

ANALOGS AND DERIVATIVES; BIOAVAILABILITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; MALE; METABOLISM; MICELLE; ORAL DRUG ADMINISTRATION; POWDER; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; YOUNG ADULT;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CURCUMIN; FEMALE; HUMANS; MALE; MICELLES; POWDERS; SEX FACTORS; YOUNG ADULT;

EID: 84897584012     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300724     Document Type: Article

References (49)

1. Jemal, A., Murray, T., Ward, E., Samuels, A. et al., Cancer statistics, 2005. CA Cancer. J. Clin. 2005, 55, 10-30.
2. Sharma, R. A., Steward, W. P., Gescher, A. J., Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol. 2007, 595, 453-470.
3. Golombick, T., Diamond, T. H., Manoharan, A., Ramakrishna, R., Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am. J. Hematol. 2012, 87, 455-460.
4. Ide, H., Tokiwa, S., Sakamaki, K., Nishio, K. et al., Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 2010, 70, 1127-1133.
5. Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., Phisalaphong, C. et al., Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012, 35, 2121-2127.
6. Alwi, I., Santoso, T., Suyono, S., Sutrisna, B. et al., The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta. Med. Indones 2008, 40, 201-210.
7. Akazawa, N., Choi, Y., Miyaki, A., Tanabe, Y. et al., Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutr. Res. 2012, 32, 795-799.
8. Khajehdehi, P., Zanjaninejad, B., Aflaki, E., Nazarinia, M. et al., Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J. Ren. Nutr. 2012, 22, 50-57.
9. Sugawara, J., Akazawa, N., Miyaki, A., Choi, Y. et al., Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women: pilot study. Am. J. Hypertens. 2012, 25, 651-656.
10. Pareyson, D., Marchesi, C., Natural history and treatment of peripheral inherited neuropathies. Adv. Exp. Med. Biol. 2009, 652, 207-224.
11. von Geldern, G., Mowry, E. M., The influence of nutritional factors on the prognosis of multiple sclerosis. Nat. Rev. Neurol. 2012, 8, 678-689.
12. Chandran, B., Goel, A., A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother. Res. 2012, 26, 1719-1725.
13. Jurenka, J. S., Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern. Med. Rev. 2009, 14, 141-153.
14. Schaffer, M., Schaffer, P. M., Zidan, J., Bar Sela, G., Curcuma as a functional food in the control of cancer and inflammation. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 588-597.
15. Shehzad, A., Ha, T., Subhan, F., Lee, Y. S., New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur. J. Nutr. 2011, 50, 151-161.
16. Dal Piaz F, B. A., Belisario, M. A., De Tommasi, N., Thioredoxin system modulation by plant and fungal secondary metabolites. Curr. Med. Chem. 2010, 17, 479-494.
17. Karlstetter, M., Lippe, E., Walczak, Y., Moehle, C. et al., Curcumin is a potent modulator of microglial gene expression and migration. J. Neuroinflammat. 2011, 8, 125. doi:10.1186/1742-2094-8-125.
18. Belakavadi, M., Salimath, B. P., Mechanism of inhibition of ascites tumor growth in mice by curcumin is mediated by NF-kB and caspase activated DNase. Mol. Cell Biochem. 2005, 273, 57-67.
19. Kuo, C. L., Wu, S. Y., Ip, S. W., Wu, P. P. et al., Apoptotic death in curcumin-treated NPC-TW 076 human nasopharyngeal carcinoma cells is mediated through the ROS, mitochondrial depolarization and caspase-3-dependent signaling responses. Int. J. Oncol. 2011, 39, 319-328.
20. Thayyullathil, F., Chathoth, S., Hago, A., Patel, M. et al., Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells. Free Radic. Biol. Med. 2008, 45, 1403-1412.
21. Liu, H., Liang, Y., Wang, L., Tian, L. et al., In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. PLoS One 2012, 7, e48075.
22. Anand, K., Sarkar, A., Kumar, A., Ambasta, R. K. et al., Combinatorial antitumor effect of naringenin and curcumin elicit angioinhibitory activities in vivo. Nutr. Cancer 2012, 64, 714-724.
23. El-Azab, M., Hishe, H., Moustafa, Y., El-Awady el, S., Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. Eur. J. Pharmacol. 2011, 652, 7-14.
24. Eckert, G. P., Schiborr, C., Hagl, S., Abdel-Kader, R. et al., Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochem. Int. 2013, 62, 595-602.
25. Jaruga, E., Salvioli, S., Dobrucki, J., Chrul, S. et al., Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes. FEBS Lett. 1998, 433, 287-293.
26. Kurita, T., Makino, Y., Novel curcumin oral delivery systems. Anticancer Res. 2013, 33, 2807-2821.
27. Pan, M. H., Huang, T. M., Lin, J. K., Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 1999, 27, 486-494.
28. Shoba, G., Joy, D., Joseph, T., Majeed, M. et al., Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998, 64, 353-356.
29. Sharma, R. A., McLelland, H. R., Hill, K. A., Ireson, C. R. et al., Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 2001, 7, 1894-1900.
30. Vareed, S. K., Kakarala, M., Ruffin, M. T., Crowell, J. A. et al., Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 1411-1417.
31. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M. et al., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21, 2895-2900.
32. Lao, C. D., Ruffin, M. T., Normolle, D., Heath, D. D. et al., Dose escalation of a curcuminoid formulation. BMC Complement. Alter. Med. 2006, 6, 10. doi:10.1186/1472-6882-6-10.
33. Garcea, G., Berry, D. P., Jones, D. J., Singh, R. et al., Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 120-125.
34. Sharma, R. A., Euden, S. A., Platton, S. L., Cooke, D. N. et al., Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004, 10, 6847-6854.
35. Carroll, R. E., Benya, R. V., Turgeon, D. K., Vareed, S. et al., Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res. (Phila) 2011, 4, 354-364.
36. Ringman, J. M., Frautschy, S. A., Teng, E., Begum, A. N. et al., Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res. Ther. 2012, 4, 43. doi:10.1186/alzrt146.
37. Antony, B., Merina, B., Iyer, V. S., Judy, N. et al., A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J. Pharm. Sci. 2008, 70, 445-449.
38. Cuomo, J., Appendino, G., Dern, A. S., Schneider, E. et al., Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J. Nat. Prod. 2011, 74, 664-669.
39. Sasaki, H., Sunagawa, Y., Takahashi, K., Imaizumi, A. et al., Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull. 2011, 34, 660-665.
40. Kanai, M., Imaizumi, A., Otsuka, Y., Sasaki, H. et al., Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother. Pharmacol. 2012, 69, 65-70.
41. Gota, V. S., Maru, G. B., Soni, T. G., Gandhi, T. R. et al., Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem. 2010, 58, 2095-2099.
42. Savjani, K. T., Gajjar, A. K., Savjani, J. K., Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012, 2012, 195727. doi:10.5402/2012/195727.
43. Brunner, G., Applications of supercritical fluids. Ann. Rev. Chem. Biomol. Eng. 2010, 1, 321-342.
44. Heath, D. D., Pruitt, M. A., Brenner, D. E., Rock, C. L., Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 783, 287-295.
45. Stahl, W., van den Berg, H., Arthur, J., Bast, A. et al., Bioavailability and metabolism. Mol. Aspects Med. 2002, 23, 39-100.
46. DiSilvestro, R. A., Joseph, E., Zhao, S., Bomser, J., Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr. J. 2012, 11, 79. doi:10.1186/1475-2891-11-79.
47. Meibohm, B., Beierle, I., Derendorf, H., How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. 2002, 41, 329-342.
48. Ono, K., Hasegawa, K., Naiki, H., Yamada, M., Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75, 742-750.
49. Lim, G. P., Chu, T., Yang, F., Beech, W. et al., The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21, 8370-8377.